Navigation Links
Scientists find Achilles’ heel of cancer cells
Date:11/5/2012

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

In the cell, histone deacetylases (HDAC) are responsible for removing small chemical tags called acetyl groups from histone proteins. Histones serve as coils the genetic material wraps around in the nucleus. The presence or absence of acetyl tags determines where genetic material is accessible and can get transcribed.

Now this is where Witt and his colleagues suspect the reason for the problems in clinical application of HDAC inhibitors. Currently available substances equally block all members of the large family of HDAC enzymes. Thus, they interfere with vital cellular functions and also harm healthy cells. This can lead to severe side effects preventing their administration at a sufficient dosage.

Searching for a solution to this dilemma, Witt's team came across a member of the HDAC family, HDAC11, which was identified only recently. The researchers could show that many cancer cells, including cells of breast, liver and renal cancers, produce extraordinary high levels of HDAC11. This has not been observed in healthy cells, and hardly any specific functions of HDAC11 are known there. "It therefore seemed obvious that a specific HDAC11 inhibitor would specifically target tumor cells, where this enzyme appears to play a critical role," says Dr. Hedwig Deubzer, first author of the article.

As there are no specific HDAC11 inhibitors available yet, the team took a different approach to verify their hypothesis. Using molecular techniques, they turned off production of HDAC11 in breast, colon, prostate and ovarian cancer cell lines and likewise in control cells of healthy tissues. The result: Cancer cells without HDAC11 were impaired in viability and more often underwent cell death (apoptosis). By contrast, loss of HDAC11 did not cause any noticeable changes in normal cells.

"The result suggests that selective blocking of HDAC11 would act exclusively on tumor cells," says Hedwig Deubzer. Numerous highly specific inhibitors against various cancer-relevant enzymes have been developed in recent years, with some of them already approved as drugs. This encourages the Heidelberg research team, jointly with Bayer Healthcare, to look for a suitable substance that specifically targets HDAC11.

HDAC inhibitors belong to a group of drugs classified by researchers as "epigenetically effective" drugs. These agents influence the chemical tags that a cell attaches directly to the genetic material or to the packaging proteins of genetic material such as histones. These tags play a substantial role in regulating gene activity. In the past few years, evidence has been accumulating that epigenetic tagging defects promote cancer development. Novel agents such as HDAC inhibitors are intended to correct such defects.


'/>"/>

Contact: Anke Retzmann
A.Retzmann@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related medicine news :

1. UC Davis scientists identify new target for lung cancer treatment
2. Scientists create endless supply of myelin-forming cells
3. Scientists decode software instructions of aggressive leukemia cells
4. Canadian scientists discover cause of high cholesterol
5. Scientists step up hunt for bacterial genes tied to Lyme disease
6. Scientists to study the role genes play in treating TB
7. Kessler Foundation scientists awarded New Jersey grants for brain injury research
8. Scientists Focus on Factors Behind Asthma Attacks
9. Einstein-Montefiore scientists awarded 2 NCI Provocative Questions grants
10. Leading stem cell scientists to focus on diabetes, eye diseases at Cedars-Sinai symposium
11. Diets High in Fructose May Harm Liver in Some, Scientists Warn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... D.C. (PRWEB) , ... April 28, 2016 , ... The ... and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition for ... the medical community effective October 1, 2016. , Sarcopenia is defined as a combination ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing pharmacy ... prescription medications from over 180 American pharmaceutical companies for $35 per month, ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... offering, the Protocol Calendar Exchange , is officially open to all sponsors ... calendars available for sites to download into their clinical trial management system (CTMS), ...
(Date:4/28/2016)... ... 2016 , ... On Thursday, April 14 orthopaedic surgeon ... Institute in Vail, Colorado, attended the American Academy of Orthopaedic Surgeons (AAOS) ... musculoskeletal disorders that are affecting millions of Americans today. Dr. LaPrade and many ...
(Date:4/28/2016)... Valley, California (PRWEB) , ... ... ... Inc. (AGNITY) a leading global provider of intelligent business communication applications and ... and go-live of its Number Portability solution at Bestel’s Communications Network. ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... CLEVELAND , April 26, 2016 ... is forecast to expand 4.9 percent annually to ... and other healthcare facilities to decrease rates of ... infection prevention supplies, equipment, and services.  Although declining, ... is significantly above targeted levels set by the ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
(Date:4/26/2016)... , April 26, 2016 ... Microbial identification Market Size, Share, Development, Growth ... Insights by Product (Consumables, Instruments and Software ... Genotypic Method), by Application (Diagnostic Application, Food ... Application) and by End User (Hospitals, Pharmaceutical ...
Breaking Medicine Technology: